| Code | CSB-RA023984MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ADG206, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing immune cell activation, proliferation, and survival. Upon binding with its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify T cell-mediated immune responses and promote long-term immunological memory. This pathway has garnered significant attention in cancer immunotherapy research, as TNFRSF9 agonism can enhance anti-tumor immunity by boosting cytotoxic T lymphocyte activity and overcoming immunosuppressive tumor microenvironments.
ADG206 represents an investigational agonistic antibody designed to stimulate TNFRSF9 signaling for therapeutic benefit in oncology. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF9-mediated immune activation mechanisms, exploring combination immunotherapy strategies, and evaluating biomarkers associated with 4-1BB pathway engagement in preclinical models.
There are currently no reviews for this product.